News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Blog
Mar 28, 2025, 14:38
Jarushka Naidoo: Results from the Phase II KROCUS Trial at ELCC 2025 presented by Marga Majem
Blog
Mar 28, 2025, 14:31
Jordi Remon: Adagrasib and pembrolizumab show impressive mPFS in KRAS G12C mutant NSCLC
Blog
Mar 28, 2025, 14:24
NCODA Hosts Third Annual International Executive Council Summit
Blog
Mar 28, 2025, 14:22
Susanna Fletcher Greer: V Foundation researchers are making CAR T Cell therapy more effective against relapsed leukemia
Blog
Mar 28, 2025, 14:14
Hil Moss: National Coalition for Cancer Survivorship Cancer Policy Roundtable
Blog
Mar 28, 2025, 14:10
Robert F. Kennedy Jr.: The Administration for a Healthy America will improve the health of the entire nation
Oncolibrary
Mar 28, 2025, 14:09
Ocular Side Effects Of Immune Checkpoint Inhibitors
Blog
Mar 28, 2025, 14:03
Shankar Siva: OMET trial in oligometastatic HNSCC
Blog
Mar 28, 2025, 13:38
Patrick Hwu: Uptick in young patients being diagnosed with colorectal cancer
Blog
Mar 28, 2025, 13:36
King Charles III Hospitalized Following Side Effects from Cancer Treatment
Blog
Mar 28, 2025, 13:29
Elvina Almuradova: Second interim analysis confirms the benefit from addition of Pembrolizumab to CRT
Blog
Mar 28, 2025, 13:19
Giannis Mountzios: Keith Kerr on the role of pathology in the optimal management of Thoracic Malignancies